Brian Kaspar

Brian Kaspar currently serves as the Chief Scientific Officer at Insmed Incorporated, where innovative research focuses on technologies such as artificial intelligence-driven protein engineering and gene therapy. In addition to this role, Brian is a Board Member at AccuGen Group and Vinta Bio, and a Scientific Advisory Board Member and Board of Directors member at Endsulin. Brian co-founded Milo Biotechnology, a company dedicated to developing gene therapy treatments for muscular disorders. Brian's previous experience includes serving as Chief Scientific Officer and SVP at AveXis, Inc., where groundbreaking work was done on gene therapies for rare neurological genetic diseases. Brian's academic background includes a Ph.D. in Molecular Pathology from UC San Diego and a Bachelor of Science in Neurobiology and Neurosciences from the University of Illinois Urbana-Champaign, supplemented by a faculty position at the Research Institute at Nationwide Children's Hospital, focusing on neuromuscular and neurodegenerative diseases, as well as postdoctoral research at the Salk Institute for Biological Studies.